12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Alnylam, Arrowhead deal

Alnylam granted Arrowhead an exclusive, worldwide license to IP covering an RNAi therapeutic to treat HBV infection. Alnylam is eligible for milestones and royalties. Additionally,...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >